In nonclinical models, cibisatamab demonstrated the ability to increase T-cell infiltration in CEA-expressing tumours, thus converting non-inflamed programmed death-ligand 1 (PD-L1)–negative tumours into highly inflamed PD-L1–positive tumours15. Here, CEACAM5 is linked to neoplasm.